Telix Pharmaceuticals falls on dilution risks in $1.65bn ITM deal
Shares of Telix Pharmaceuticals fell as much as 10.2% to A$16.030, their biggest intraday percentage fall since Aug. 28, 2025. The biopharma company agreed to buy Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis. "Sharp negative reaction in Telix reflects the dilut